Coherus Oncology, Inc. (CHRS) stock
Close on Nov 12, 2026Market cap $83.20MP/E –Yield –
Coherus Oncology, Inc. grew revenue 44.4% to $53.64M over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $83.20M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $83.20M
- P/E ratio
- –
- Price to sales
- 1.55
- Price to book
- 3.30
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $53.64M
- Net income
- -$135.94M
- EPS, diluted
- $1.43
- Book value per share
- $0.16
- Diluted shares
- 155M
Trading
- Next earnings
- Mar 8, 2027 (estimated, during market hours)
- Previous close
- $0.58
- Open
- $0.57
- Day's range
- $0.51 – $0.58
- Volume
- 4,505,348
- Average volume (20 days)
- 2,181,286
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.39
- 52-week range
- $0.57 – $2.62
- RSI (14 days)
- 30.3
- Volatility (1 year)
- 87.8%
- Relative volume
- 4.03×
- WACC
- 11.8%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CHRS | S&P 500 | Difference | CHRS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -47.7% | -2.7% | −45.0 pts | ||
| 3 months | -54.0% | -1.7% | −52.2 pts | ||
| Year to date | -62.1% | +11.9% | −74.0 pts | ||
| 1 year | -60.4% | +12.0% | −72.4 pts | ||
| 3 years | -66.1% | +78.2% | −144.3 pts | -30.3% | +21.2% |
| 5 years | -97.1% | +73.2% | −170.3 pts | -50.8% | +11.6% |
| 10 years | -98.1% | +309.6% | −407.7 pts | -32.6% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Coherus Oncology filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Results
About Coherus Oncology
Biological Products, (No Diagnostic Substances)
Coherus Oncology, Inc. is a biopharmaceutical company that develops and commercializes immuno-oncology treatments for various cancers. Its primary commercial product is LOQTORZI, an FDA-approved immune checkpoint inhibitor prescribed for adults with advanced nasopharyngeal carcinoma. The company's clinical pipeline includes two mid-stage candidates: casdozokitug, an antibody targeting IL-27 for liver cancer and other malignancies, and tagmokitug, an antibody targeting CCR8 for solid tumors. Coherus sells LOQTORZI through wholesale specialty distributors, primarily McKesson, Cencora, and Cardinal Health, to reach healthcare providers and patients.
Company profile, executives and historyCoherus Oncology stock: common questions
What is Coherus Oncology's stock price?
CHRS closed at $0.54 on Nov 12, 2026, down 7.55% on the day. Over the past 52 weeks it traded between $0.57 and $2.62.
What is Coherus Oncology's market cap?
Coherus Oncology was worth $83.20M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
How much revenue does Coherus Oncology make?
Coherus Oncology reported revenue of $53.64M for the twelve months to Sep 30, 2026, up 44.4% from a year earlier.
Does Coherus Oncology pay a dividend?
No. Coherus Oncology has not paid a cash dividend over the last twelve months.
When does Coherus Oncology report earnings next?
Coherus Oncology is expected to report Q4 FY2026 results on Mar 8, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has CHRS stock performed over the past year?
Including dividends, CHRS returned -60.4% over the past year, against +12.0% for the S&P 500.
How many CHRS shares are sold short?
13M shares were sold short at the latest FINRA report, 8.34% of the float, or 8.2 days of average trading volume.
Who are Coherus Oncology's competitors?
Companies most similar to Coherus Oncology by business, industry and size include ADAPY, STRO, BDTX, IVVD, AUTL.
See a number that looks wrong?